Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Next Previous
Trial Profile

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Anastrozole; Celecoxib
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 11 Apr 2021 Results of a secondary analysis of large adjuvant endocrine therapy trials (MA.17, MA.17R and MA.27) quantify the impact of competing risks on estimates of disease recurrence and benefit from therapypublished in the European Journal of Cancer
    • 20 Dec 2017 Random assignment to celecoxib was discontinued in 2004 after randomisation of 1622 patients and these patients remained on study and were followed according to study protocol with inclusion in the comparison of exemestane versus anastrozole, according to results published in the European Journal of Cancer.
    • 20 Dec 2017 Results (n=5709) assessing histological subtype (invasive ductal or invasive lobular) as a prognostic and predictive marker for differential efficacy of anastrozole and exemestane in patients with hormone receptor-positive early breast cancer, published in the European Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top